A significant drop in share price raises concerns for investors.
Appili Therapeutics Inc experienced a steep decline in its stock price yesterday, with shares falling by 33.33% to close at CA$0.01. This sharp downturn has left investors questioning the company's stability and future prospects.
Advertisement
Earn cash back with a smarter spending account
Open a KOHO account and start earning on everyday purchases — no annual fee on the base plan.
Appili Therapeutics Inc
APLI.TO
APLI.TO
Appili Therapeutics Inc
WealthAwesomeMarket cap
$1.99M
52W high
$0.04
52W low
$0.01
1W change
+0.00%
Beta
-0.20
Analyst Price Targets
Based on analyst covering APLI
Wall Street analysts forecast APLI stock price to rise 1400.0% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$0.15
+1400.0% Upside
Current Price
C$0.01
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on APLI's historical volatility
30-Day Vol
238.3%
Annualized
90-Day Vol
232.9%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.01
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.01 | C$0.00 – C$0.02 |
| 60 trading days | C$0.01 | C$0.00 – C$0.03 |
| 90 trading days | C$0.01 | C$0.00 – C$0.03 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should closely monitor Appili Therapeutics for any developments that could impact its financial health and stock performance, especially in light of recent challenges.
Stock price plummets by 33.33%
Appili's market cap now stands at CA$1,325,661, indicating a critical loss of investor confidence.
Bull case
Despite the recent setback, Appili has seen some positive movement with its LIKMEZ® product in the U.S. market. If the company manages this momentum well, it could lead to future growth opportunities.
Bear case
The significant drop in stock price highlights ongoing worries about the viability of Appili's programs. This is especially true after the Notice of Termination for the VXV-01 program, which may affect its operational capabilities.
Recent Performance Overview
Advertisement
Yesterday's trading session saw Appili Therapeutics Inc's stock price fall sharply by 33.33%. This decline is particularly concerning given the company's recent challenges, including the termination of its VXV-01 program. Investors are now left to ponder the implications of this downturn on the company's future.
Implications of the Decline
The significant drop in stock price reflects broader concerns about Appili's operational viability. With a market cap now at CA$1,325,661, the company faces an uphill battle to regain investor confidence. Stakeholders should remain vigilant for any news that could affect the company's trajectory, especially regarding its ongoing projects and financial health.
Looking Ahead
As Appili Therapeutics navigates this challenging period, it will be crucial for the company to communicate effectively with investors and stakeholders. Future announcements regarding its remaining programs and potential partnerships will be key to determining whether it can recover from this setback.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
